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Abstract 
Objective: Chronic kidney disease (CKD) is one of the most serious complications in obesity induced 
type 2 diabetes mellitus (T2DM). Body mass index (BMI), waist to hip ratio (WHR), waist 
circumference (WC) and waist to height ratio (WHtR) are recognised as sensitive measures for obesity 
which is suggested as a risk factor of greater importance for T2DM. We aimed to investigate the 
association of BMI, WC, WHR and WHtRwithCKD prevalence in overweight T2DM patients. 
Design, Subjects and Methods:  We sequently obtained 125 overweight T2DM patients comming for 
their comprehensive in-patient annual visit. Metabolic profiles and anthropometric indices were 
measured and calculated,urine albumin excretion (UAE) was determined as the mean of 24-h urine 
from two consecutive days and serum creatinine was measured from fasting blood sample and used to 
calculate the estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula.Patients were divided in two groups according to 
CKD prevalence. Results: Sixty five patients (52%) were male, median age 58 years and 11 years 
disease duration. Thirty six (28.8%) met diagnostic criteria for CKD. The WHtR and waist 
circumference were higher in the group with CKD. WHtR correlated positively with UAE (r=0.828, 
p<0.001) and negatively with eGFR (r=-0.262, p=0.015). No significant correlation was observed with 
waist circumference in relation to UAE (r=0.111, p=0.335) nor eGRF (r=-0.154. p=0.121). WHtR 
yielded the significant and great OR in association to nephropathy after adjustment for all confounding 
risk factors. 
Conclusion:WHtR might be of a greater importance in association to CKD compared to other 
anthropometric parameters that indicate central obesity. Whether it is a best measure of central obesity 
and its exact role in CKD pathology is yet to be investigated.  
Key words: chronic kidney disease, central obesity, type 2 diabetes mellitus, waist-to-height ratio  
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Introduction 
The prevalence of type 2 diabetes mellitus (T2DM) is globally rising at an alarming rate. Micro- and 
macrovascular complications are the leading cause of morbidity and mortality in diabetic 
patients(1).Obesity is considered a major risk factor for T2DM development.butNotonly total body fat 
is important but also its distribution (3). Several independent studies suggest that anthropometric 
measuresofcentral obesity are superior in predicting T2DM than those of general obesity (4-7). 
Anthropometric measuresare commonly used to assess disease risk factors as they are easy to monitor 
at the community level (8). Body mass index (BMI) which relates weight to height is most frequently 
used to estimate the prevalence of obesity within a population.BMI ≥ 25 kg/m2 is associated with 
increased morbidity, primarily T2DM, while BMI ≥30 kg/m2 is associated with an increased risk of 
morbidity and mortality, mainly because of diabetes (9, 10). However, BMI does not distinguish fat 
from muscle weight nor can distinguishfat distribution (11). Waist circumference (WC) and waist-to-
hip ratio (WHR) have been proposed as tools to detect central obesity, but WC might over- or under- 
evaluate central obesity prevalence for tall or short individuals with similar waist circumference while 
WHR has a limitation in case of weight loss when both sizes decrease andthe changes in ratio remain 
rather small (12). Waist-to-height ratio (WHtR) is an anthropometric proxy ofcentral obesity that 
corrects WC for height and is suggestedas an index that can be used in different ethnic, age and sex 
groups for central obesity screening (13-15). 
Chronic kidney disease (CKD) i.e. diabetic nephropathy is one of the most serious complications of 
central obesity-induced diabetes (T2DM) (16). Moreover, in the industrial nations T2DM is asingle 
most frequent cause of end-stage renal disease (17). The data from the Framingham Heart study 
thatincluded over 2,600 patients with no CKD at baseline showed an increased risk indeveloping stage 
3 CKD in obese (BMI ≥ 30 kg/m2) compared to non-obese subjects (18). The precise mechanism by 
whichcentral obesity contributes to the development and/or CKD progression is not completely 
understood.However, it is a well-recognized risk factor for T2DM and hypertension development 
which are leading causes of CKD (19). Elevated fasting blood glucose level, hypertriglyceridemia and 
low high-density lipoprotein cholesterol (HDL-C)are also proposed risk factors for CKD development 
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(20).All of those can be found in individuals with central obesity and/or T2DM. WHR shows an 
association with CKD in diabetic as well as non-diabetic population (21, 22). The association of 
WHtRwith CKD in non diabetic subjects was also recently described (23, 24). Consisted with this, the 
aim of our study to investigate the association of BMI, WC, WHR and WHtRwithCKD prevalence in 
overweight T2DM patients which to the best of our knowledge it has not been investigated yet. 
 
 
Subjects and Methods 
This was a cross-sectional study of a sequential sample comprising T2DM 125 patients of both 
genders ,BMI ≥29 kg/m2coming for their comprehensive annual review. Patients with thyroid, kidney 
(other than diabetic neprhropathyand end stage renal disease),liver disorders, psychiatric diseases, 
non-essential hypertension or any chronic or acute infections were not included in the study. Data 
were collected from July 2012 to May 2013.The study protocol complies with the Declaration of 
Helsinki and local institutional guidelines.Itwas approved by the local ethics committee. Written 
informed consent was obtained from all participants. 
All subjects were studied in the morning between 08:00 and 09:30 hours after an overnight fast. Basic 
anthropometric measurements were performed on all study subjects by the same physician. WC was 
measured on bare skin as the narrowest circumference between the 10
th
 rib and the iliac crest with 
tailor meter. Weight was measured by the physician using a balanced-beam scale with light clothing 
without shoes and expressed in kilograms (kg).Height was measured using a wall-mounted 
stadiometer and expressed in centimetres (cm) according to the NHANES III study (25). A steel tape 
measure was used to measure the women's waist circumference, midway between the lower rib margin 
and the iliac crest, and hip circumference at the widest point between the iliac crest and buttock. The 
circumferences were measured in a standing position and to the nearest 0.5 cm (25). BMI was 
calculated as weight in kilograms divided by the square of height in meters (kg/m2). WHR and WHtR 
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were calculated by dividing the waist circumference by the hip circumference and the body height, 
respectively. 
Urine albumin excretion (UAE) was measured from at least two 24-h urine samples and determined as 
the mean of 24-h urine from two consecutive days to minimize variability. Serum creatinine was 
measured in fasting blood sample. Data on serum creatinine levels, age, sex and race were used to 
calculate the estimated glomerular filtration rate (eGFR) using the 
ChronicKidneyDiseaseEpidemiologyCollaboration (CKD-EPI) formula, whichwasshown to 
beaccurateindetermining renal function in diabetic patients with normal renal function (26, 27) in 
order to determine the presence of diabetic nephropathy.  Chronic kidney disease was defined as the 
presence of impaired eGFR (less than 60 mlmin
-1
1.73m
-2) and/oralbuminuria ≥30 mg/24hin two 
measurements at least 3 months apart (28). 
Blood pressure was measured in the sitting position with a mercury sphygmomanometer with a cuff 
appropriate to the length and circumference of the arm after a resting period of 10 minutes and 
expressed in mmHg. Patientstakingbloodpressuremedications or withblood pressure >140/90 mmHg 
were considered to have hypertension. Fasting venous blood samples were collected for the 
determination of biochemistry panel, lipid profile status, HbA1c. Cholesterol and triglycerides in 
serum were measured by an enzymatic colorimetric method. Beside the lipid profile status, 
thosepatientswithhistoryof lipid-loweringagentsconsumptionwereconsidered to havedyslipidaemia.  
HbA1c was measured spectrophotometrically by turbidimetric immuno-inhibition (Olympus AU600, 
Beckman-Coulter, USA). 
 
The data distribution was assessed by Shapiro-Wilk test. All the continuous variables are reported as 
mean ± standard deviation i.e. median and range, whereas categorical variables were reported as 
numbers and percentages. The differences between two study groups were tested by Student’s t-test 
while the categorical variables were analysed by the χ2 test. Correlations between WC, WHtR, UAE 
and eGFR  were determined using Pearson’s correlation coefficient. All the tests were two-sided. The 
association between WHtRand CKD prevalence was further evaluated in multivariate logistic 
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regression. Adjustments were performed for gender, age, disease duration, HbA1c value, hypertension 
(i.e. ACEI use), dyslipidaemia (i.e. the use of statins) and smoking status Statistical interference is 
based on 95% confidence intervals (CIs) and 5% P values. All statistical analysis was conducted using 
the statistical package Statistical Package for the Social Sciences (SPSS) ver.17.0 and MedCalc 12.2.2 
for Windows. 
 
Results 
Among the 125 T2DM patients, sixty five (52%) were male and 60 (48%) female median age 58 years 
and 11 years disease duration. Table 1.summarizes the descriptive anthropometric characteristics and 
biomedical data as well as CKD prevalence all study participants. One hundred and fourteen 
patients  (91.2%) had hypertension and 100% of them were onangiotensin-converting enzyme 
inhibitors (ACEI). Thirty six (28.8%) met diagnostic criteria for CKD. The group of patients with 
CKD compared to group without CKD showed no significant difference in age (56 vs 58 years, 
p=0.166), gender (53.5% vs 50.5% males), disease duration (median 11 years for both groups; range 
2-24 years vs 1-30 years, p=0.760), glycated hemoglobin (HbA1c) (8.64 vs 8.63%, p=0.946) , 
dyslipidemia(75 vs 74.16%, p=0.846)nor the ACEI (91.6 vs 91.02%, p=0.961) use. The WHtR and 
waist circumference were higher in the group with CKD (Table 2.). WHtR correlated positively with 
UAE (r=0.828, p<0.001) and negatively with eGFR (r=-0.262, p=0.015) while no significant 
correlation was observed with waist circumference in relation to UAE (r=0.111, p=0.335) nor 
eGRF(r=-0.154. p=0.121). In the logistic regression models WHtRremained significantly associated 
with CKD presence after appropriate adjustments for all possible confounding risk factors (Table 3.). 
Discussion 
This cross-sectional study was designed in order to examine the association of several most frequently 
used obesityanthropometric parameters with CKD in overweight T2DM patients. Itrevealed that those 
individuals with CKD have higher WC and WHtR which is in support to the hypothesis that central 
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obesity is associated with CKD in this patient population (19-22). However, only WHtRcorrelated 
both with eGFR and UAE. This is particularyimportant since it is not an uncommon finding that 
elderly patients with T2DM, especially those with recent onset of the disease, have mildly impaired 
renal function in setting of normal UAE. Our finding suggests that WHtR might be associated with 
diabetic glomerulosclerosis. Additionally, WHtR remained positively associated with CKD when 
calculating ORs adjusted for further influencing parameters proven to affect CKD in T2DM 
population (29). This finding ispartially  in support to Tseng (2005) (30) whodemonstrated that WC 
and WHtRare the best indicators of microalbuminuria in Chinese T2DM woman but not man. 
Although there are several studies have linking microalbuminuria and variable proteinuria degrees to 
obesity (31, 32)the exact mechanisms linking central obesity as a causial factor of renal injury is still 
largely speculated. Diabetes related abnormalities: insulin resistance (IR), hyperglycaemia, 
dyslipidaemia along with oxidative stress and low grade inflammation are attenuated by hormonally 
active visceral adipose tissue (24, 33). This metabolic milieu represents a cluster ofatherosclerosis risk 
factorsin general population (34, 35) but it might cause renal injuryas well. Several studies indicate 
that central adipose tissue contributesto the renin-angiotensin-system (RAS) hormones disruption i.e. 
increase in circulating levels of renin, angiotensinogen, angiotensin-converting enzyme (ACE), 
aldosterone and angiotensin II (AngII) (36). AngII is widely known to adversely affect the progression 
of renal disease by a sum of mechanismsItleads to induction of intrarenal inflammation and cell 
apoptosis which is why ACEI found their place in CKD prevention and treatment (37). We did not 
find the difference in the use of ACE inhibitors (ACEI) between two study groups. Moreover, in the 
regression analysis after adjustment for the ACEI use, WHtR remained positively associated to CKD. 
Dyslipidaemia, defined as high total cholesterol, high low-density lipoprotein cholesterol and low 
high-density cholesterol with race cut-off’s  may cause renal mesangial and epithelial cell injury and 
promote renal disease progression (38-40). We did not observe the difference in dyslipidaemia 
prevalence between our two study groups, probably because its high prevalence rate in both study 
groups. Therefore, there is practically no doubt that central obesity plays an important role in CKD 
development and progression. Both total and visceral/central fat can be precisely measured by double 
8 
 
energy X-ray densitometry (DXA), computerised tomography magnetic resonance imaging (41). Due 
to high costs and complex procedures these methods are not likely to be used in large epidemiological 
studies or individual physician assessment, thus there is a need for a simple to perform and accurate 
anthropometric test in order to indicate body fat distribution and their accuracy in CKD development 
and progression risk. In support to this study, Barreto Silva et al (2013) (24) evaluated the precision of 
different anthropometric measures of abdominal adiposity in non-diabetic non-dialysed patients with 
CKD. They studied the accuracy of the following anthropometric indices: WC, WHR, conicity index 
and WHtR to assess abdominal adiposity and compared them using trunk fat by dual x-ray 
absorptiometry (DXA) as a reference method but they also explored their association with insulin 
resistance using HOMA-IR. Among studied indices, WHtR was the only one to show correlation with 
DXA trunk fat after adjusting for confounders and also indicated high HOMA-IR. 
Our study results indicate that WHtRis strongly associated with CKD and that it might be of a great 
importance in itsdevelopment compared toother anthropometric parameters that indicate. central 
obesity. However, it is important to emphasise the study limitations: first, this study was cross-
sectional which clearly diminishes its power any general conclusions cannot be made. Second, we did 
not perform the body composition analysis so we cannot strongly claim that WHtR is the best 
indicator of central obesity. However, the relationship between WHtR and CKD progression in the 
prospective analysis would be of great interest.  
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Table 1. Baseline characteristics of the study participants 
Hypertension, i.e. the use of ACEI in therapy 
n (%) 
114 (91.2) 
Total plasma cholesterol (mmol/L) 5.07 (3.02-7.41) 
HDL cholesterol (mmol/L) 1.24 (0.70-2.49) 
LDL cholesterol (mmHg) 2.95 (1.03-5.81) 
Tryglicerides (mmol/L) 2.47 (0.76-10.83) 
Dyslipidemia , n (%) 93 (74.4) 
Creatinine (µmol/L) 74 (46-182) 
UAE (mg/dU) 223.29 (2.80-4773.27) 
eGFR ( mL/min/1.73 m
2
) 83 (41-118) 
Current smoker, n( %) 105 (84) 
Chronic kidney disease prevalence, n(%) 
- Based only on eGFR <60 ml/min/1.73 
m
2
, n(%) 
- Based only on UAE>30 mg/24h, n(%) 
- Based on eGFR <60 ml/min/1.73 m2+ 
UAE>30 mg/24h 
36 (28.8) 
3 (2.4) 
 
26 (20.8) 
7 (5.6) 
*Legend: ACEI- angiotensin converting enzyme inhibitors; BMI-body mass index, eGFR-
estimated glomerulal filtration rate, UAE-urin albumin excretion rate 
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Table 2. Differences in anthropometric indices of central obesity according to the CKD 
prevalence in obese T2DM patients 
Variable T2DM patients 
without CKD 
T2DM patients with 
CKD 
p value 
Waist circumference 
(cm) 
117 (92-148) 119 (88-192) 0.069 
WHR 0.987 (0.795-1.243) 1.011(0.842-1.401) 0.056 
WHtR 0,666 (0.321-0.887) 0.710 (0.531-1.191) 0.031 
BMI (kg/m
2
) 37.58±4.12 38.93±5.80 
 
0.033 
*Legend: WHR-waist-to-hip ratio; WHtR-waist-to-height ratio; BMI-body mass indey 
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Table 3. Odds ratio for nephropathy  for one standard deviation increase in weight- to- height ratio adjusted by other risk factors: gender, age, 
disease duration, HbA1c value, hypertension (i.e. the use of ACEI), dyslipidaemia (i.e. the use of statins) and smoking status 
 Crude Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
CHRONIC 
KIDNEY 
DISEASE 
PRESENCE 
1.625(1.103-
1.865) 
p<0.001 
1.680(1.147-
1.880) 
p=0.013 
1.705(1.174-
1.895) 
p=0.011 
1.700(1.135-
1.896) 
p=0.023 
1.700(1.134-
1.896) 
p=0.023 
1.699(1.130-
1.896) 
p=0.024 
1.697 (1.122-
1.895) 
p=0.030 
*Model 1: adjusted by age and gender; Model 2: adjusted by age, gender and disease duration; Model 3; adjusted by age, gender, disease duration and HbA1c; Model 4: adjusted by age, gender, disease duration, HbA1c 
and dyslipidaemia; Model 5: adjusted by age, gender, disease duration, HbA1c, dyslipidaemia and artherial hypertension; Model 6: adjusted by age, gender, disease duration, HbA1c, dyslipidaemia, artherial 
hypertension and smoking status
